HF
AVBP icon

HRT Financial’s ArriVent BioPharma AVBP Stock Holding History

HRT Financial’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21M Buy
121,224
+74,171
+158% +$2.19M 0.01% 1251
2026
Q1 		$1.08M Sell
47,053
-6,371
-12% -$144K ﹤0.01% 2007
2025
Q4 		$1.07M Buy
+53,424
New +$1.11M ﹤0.01% 1668
2025
Q3 		– Sell
-25,346
Closed -$551K – 3811
2025
Q2 		$551K Buy
+25,346
New +$526K ﹤0.01% 1557

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial's AVBP Position: Q2 2026 in Review

HRT Financial increased its ArriVent BioPharma (AVBP) stake by 158% in Q2 2026, buying an estimated $2.19M and bringing the position to 121,224 shares worth $4.21M. The position accounts for 0.01% of the portfolio, ranked #1251.

HRT Financial first reported a position in AVBP in Q2 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • HRT Financial held 121,224 shares of ArriVent BioPharma worth $4.21M as of Q2 2026.
  • HRT Financial bought 74,171 ArriVent BioPharma shares in Q2 2026, an estimated $2.19M.
  • ArriVent BioPharma made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1251 holding.
  • HRT Financial first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.